Skip to main content
SpringerLink
Log in

Ad26.COV2.S COVID-19 vaccine: TTS a rare, but serious adverse event

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. heparin-induced thrombocytopenia

Reference

  • See I, et al. Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination-United States, December 2020 to August 2021. Annals of Internal Medicine : 18 Jan 2022. Available from: URL: http://doi.org/10.7326/M21-4502

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ad26.COV2.S COVID-19 vaccine: TTS a rare, but serious adverse event. Reactions Weekly 1891, 2 (2022). https://doi.org/10.1007/s40278-022-09254-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-09254-7

Search

Navigation